Antibiotics are used far more in some countries than in others, a survey by the World Health Organization showed, suggesting that urgent action was needed to slash unnecessary consumption of the medicines.
Novartis is abandoning approximately 20 percent of the company’s research projects after a strategic review.
Evotec announced that Sanofi will be participating in an organized Public Private Partnership to further the discovery of cutting-edge therapeutic drugs in multiple areas.
The U.S. FDA approved TPOXX (tecovirimat), the first drug with an indication for the treatment of smallpox.
Allergan plans to sell off both businesses as the company’s CEO works to end a steep slide in the drugmaker’s share price.
Sanofi and Evotec started exclusive talks over accelerating research into the treatment of infectious diseases and will form a new open innovation platform in this area, led by Evotec.
German biotech firm CureVac secured more financial backing for vaccine development projects from its investor the Bill & Melinda Gates Foundation, working on jabs to prevent malaria and influenza.
Enumeral Biomedical filed for bankruptcy protection and is selling its assets to Xoma Corporation for $1.6 million.
U.S. regulators approved GlaxoSmithKline’s three-in-one inhaler for chronic lung disease, a key new product as the group strives to keep its lead in respiratory medicine.
The Bill and Melinda Gates Foundation invested up to $40 million in Oxford, UK-based Immunocore. Immunocore is a T-cell Receptor (TCR) company that has largely focused on immuno-oncology, but is making the transition to infectious diseases.